Mouse Model News and Research

RSS

Glutamatergic nerve cells regularly generated in the brain

Until only a few years ago, neurogenesis - the process of nerve cell development - was considered to be impossible in the adult brain. The textbooks asserted that dead nerve cells could not be replaced. Then researchers discovered regions in the forebrain in humans in which new nerve cells can be generated throughout life. These so-called GABAergic cells use gamma-aminobutyric acid (GABA), a neurotransmitter of the central nervous system.

1 Dec 2009

NanoViricides announces filing of its quarterly report with the SEC

NanoViricides, Inc., reports that the Company has filed its quarterly report with the SEC on November 23rd.

30 Nov 2009

ALS research collaboration receives philanthropic funding

Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).

30 Nov 2009

Novel way to fight UTIs: Research into Alzheimer's disease

Research into Alzheimer's disease seems an unlikely approach to yield a better way to fight urinary tract infections (UTIs), but that's what scientists at Washington University School of Medicine in St. Louis and elsewhere recently reported.

25 Nov 2009

Alzheimer's disease research leads to more effective UTI treatments

24 Nov 2009

Research suggests common oral bacterium may exacerbate autoimmune disease

Current research suggests that a common oral bacterium may exacerbate autoimmune disease. The related report by Nichols et al, "Unique Lipids from a Common Human Bacterium Represent a New Class of TLR2 Ligands Capable of Enhancing Autoimmunity," appears in the December 2009 issue of The American Journal of Pathology.

23 Nov 2009

New FluCide better than the older version

NanoViricides, Inc., announced today that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (www.terrapinn.com/usaflu). These data clearly established that the new version of FluCide™ is superior to the older version.

23 Nov 2009

Overexpression of NCX1 does not by itself lead to contraction abnormalities in the heart

Researchers from the Center for Translational Medicine at Thomas Jefferson University have found that the overexpression of a sodium/calcium exchanger, without changes in other ion transport pathways commonly observed in heart failure, does not by itself lead to contraction abnormalities in the heart.

23 Nov 2009

Potential therapeutic strategy to improve cognition in Down syndrome identified: DSRTF

The Down Syndrome Research and Treatment Foundation (DSRTF) announces the identification of a new potential therapeutic strategy to address cognitive decline and improve cognition in Down syndrome. The findings were published in Science Translational Medicine on November 18, 2009 by DSRTF-supported researchers, Drs. Ahmad Salehi, William Mobley, and colleagues at Stanford and UCSD Schools of Medicine.

23 Nov 2009

Low-level laser therapy increases tumour growth in skin cancer

High irradiances of low-level laser therapy (LLLT) should not be used over melanomas. Researchers writing in the open access journal BMC Cancer studied the pain relieving, anti-inflammatory 'cold laser', finding that it caused increased tumour growth in a mouse model of skin cancer.

19 Nov 2009

Possible new approach to slow the progression of cognitive decline in Down's syndrome

A study by neuroscientist William C. Mobley, MD, PhD, chair of the Department of Neurosciences at the University of California, San Diego School of Medicine, and colleagues at Stanford University Medical School has demonstrated a possible new approach to slowing the inevitable progression of cognitive decline found in Down's syndrome.

19 Nov 2009

Recent developments at Burnham Institute for Medical Research

New antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) and other pesky bacteria. Andrei Osterman and collaborators have used comparisons of bacterial genomes to identify new targets for antibiotics and produced first-generation chemical inhibitors of a class of bacterial enzymes, called NadDs (nicotinate mononucleotide adenylyltransferases).

17 Nov 2009

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases, particularly ALS and Parkinson’s disease, was found to have a positive effect in a mouse model of multiple sclerosis (MS).

16 Nov 2009

Inovio Biomedical reports financial results for the three and nine months ended September 30, 2009

Inovio Biomedical Corporation today reported financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Normal synaptic activity in nerve cells protects brain from Huntington's disease

Investigators at Burnham Institute for Medical Research (Burnham), the University of British Columbia's Centre for Molecular Medicine and Therapeutics and the University of California, San Diego have found that normal synaptic activity in nerve cells (the electrical activity in the brain that allows nerve cells to communicate with one another) protects the brain from the misfolded proteins associated with Huntington's disease.

16 Nov 2009

New gene therapy may breach the armor of cancerous tumors

The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves. Researchers at the Cornell University College of Veterinary Medicine have discovered that inactivation of a DNA repair gene called Hus1 efficiently kills cells lacking p53 -- a gene mutated in the majority of human cancers.

13 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

Gene within the pancreas affecting insulin secretion discovered

How a specific gene within the pancreas affects secretion of insulin has been discovered by researchers from the Hebrew University of Jerusalem, in collaboration with Japanese and American universities. Their work opens the way for a new understanding of possible paths to battle diabetes and diabetes-related health problems, which are on the rise all over the world.

12 Nov 2009

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today.

12 Nov 2009

Researchers identify mouse gene that reduces the accumulation Alzheimer's plaques and tangles

Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau. The amyloid and tau lowering functions of this gene were demonstrated in both human and mouse cells.

12 Nov 2009

Mouse Model News and Research

Glutamatergic nerve cells regularly generated in the brain

NanoViricides announces filing of its quarterly report with the SEC

ALS research collaboration receives philanthropic funding

Novel way to fight UTIs: Research into Alzheimer's disease

Alzheimer's disease research leads to more effective UTI treatments

Research suggests common oral bacterium may exacerbate autoimmune disease

New FluCide better than the older version

Overexpression of NCX1 does not by itself lead to contraction abnormalities in the heart

Potential therapeutic strategy to improve cognition in Down syndrome identified: DSRTF

Low-level laser therapy increases tumour growth in skin cancer

Possible new approach to slow the progression of cognitive decline in Down's syndrome

Recent developments at Burnham Institute for Medical Research

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

Inovio Biomedical reports financial results for the three and nine months ended September 30, 2009

Normal synaptic activity in nerve cells protects brain from Huntington's disease

New gene therapy may breach the armor of cancerous tumors

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Gene within the pancreas affecting insulin secretion discovered

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Researchers identify mouse gene that reduces the accumulation Alzheimer's plaques and tangles

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News